← All trials
NCT04411836
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2021
- Primary completion
- Dec 1, 2021
- Completion date
- Dec 31, 2021
- First posted
- Jun 2, 2020
- Last posted
- Jun 2, 2020
- Enrollment
- 720
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Menzies School of Health ResearchLead sponsor
- Mahidol UniversityCollaborator
- Addis Ababa UniversityCollaborator
- Ethiopian Public Health InstituteCollaborator
- University of MelbourneCollaborator
- National Centre for Parasitology, Entomology and Malaria Control, CambodiaCollaborator
- Universitas Sumatera UtaraCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.